Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Revelation Biosciences Inc (NQ: REVB ) 1.730 -0.031 (-1.75%) Streaming Delayed Price Updated: 3:59 PM EDT, Jul 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Revelation Biosciences Inc < Previous 1 2 Next > Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity June 24, 2024 From Revelation Biosciences, Inc. Via Business Wire Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini June 13, 2024 From Revelation Biosciences, Inc. Via Business Wire Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 May 10, 2024 From Revelation Biosciences, Inc. Via Business Wire Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 March 22, 2024 From Revelation Biosciences, Inc. Via Business Wire Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024) March 13, 2024 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference March 12, 2024 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini March 04, 2024 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) February 13, 2024 From Revelation Biosciences Inc. Via Business Wire BioMedNewsBreaks – Revelation Biosciences Inc. (NASDAQ: REVB) Secures ~$6.2M in Public Offering February 08, 2024 Via Investor Brand Network Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering February 05, 2024 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering February 01, 2024 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) January 30, 2024 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024 January 23, 2024 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023 November 13, 2023 From Revelation Biosciences, Inc. Via Business Wire Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies October 12, 2023 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference October 04, 2023 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors October 02, 2023 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023 August 11, 2023 From Revelation Biosciences Inc. Via Business Wire REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders June 29, 2023 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal June 12, 2023 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress May 22, 2023 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress March 30, 2023 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board March 13, 2023 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference March 06, 2023 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering February 13, 2023 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering February 09, 2023 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300 February 07, 2023 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders January 31, 2023 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023 January 10, 2023 From Revelation Biosciences Inc. Via Business Wire Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model November 18, 2022 From Revelation Biosciences Inc. Via Business Wire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.